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lished algorithm to assess quality. Evaluation criteria included
methodological characteristics (perspective, selection of com-
parators, and modeling framework), health care system charac-
teristics (relevance and applicability of clinical, treatment pattern
and cost data), population characteristics (generalizability), and
implications. RESULTS: Large variation in study quality was
observed, particularly with outcome data and treatment pat-
terns. We found that data on the effectiveness of drugs was typ-
ically extracted from clinical trials that did not include an Asian
population, used inappropriate comparators and involved prac-
tice patterns that were not consistent with standards of care in
Korea. With respect to treatment patterns, the most frequent sit-
uation relied on expert opinion from academic physicians in spe-
cialty practice. The Korean National Health Insurance Claims
Database was a good source of disease speciﬁc costs, but was
rarely used. Furthermore, the database failed to capture non-
covered services. Preference measures, when used, were not
elicited from the Korean population. Most studies (80%) did not
clarify the funding source. CONCLUSIONS: If the Korean eco-
nomic evaluation policy is to provide meaningful data for deci-
sion makers, the quality of cost-effectiveness studies will need 
to improve dramatically. This may involve access to or creation
of better data, more diverse funding, improved training of
researchers and evaluators, and partnerships with technology
manufacturers.
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OBJECTIVES: To implement a computerized, centralized, drug
prior-authorization process in a national managed care organi-
zation to control utilization and expenditures of expensive 
medications and to ensure uniformity of authorization criteria
throughout the organization. METHODS: This program was
implemented in the Leumit Health Fund, a HMO operating in
Israel. The HMO’s Medical Division has formulated a drug
policy mandating prior-approval by the Central Medicines
Department for expensive drugs. Additionally, these products
may only be dispensed from HMO owned and operated phar-
macies. To expedite this authorization process, a special com-
puter program was developed which operates under the HMO’s
electronic patient record (EPR) system. Upon prescribing one of
these drugs, a window automatically appears instructing the
physician to press a function key for transmission of an autho-
rization request to the Medical Division for approval of HMO
coverage. Two lines are provided to enter supplementary infor-
mation. The patient is then given a computer-generated pre-
scription which prior to approval, cannot be dispensed via the
HMO’s pharmacy dispensing program which is integrated with
the EPR. The distribution of drugs requested by class, and pro-
portion of requests rejected for the year 2003 was evaluated. The
aggregate monetary value of the requests denied was evaluated.
RESULTS: Throughout the year 2003, 38,490 requests were 
submitted, 44.88% of which were denied. The distribution 
of requests by drug or drug class was: Antineoplastic and
immunomodulating agents 15.58%; neurologicals (not including
anti-epileptics) 14%; newer insulins and rosiglitazone 12%;
ocular lubricants (for patients not suffering from FD or CF)
10.55%; angiotensin receptor blockers 10.24%; clopidogrel
7.18%; other 30.45%. The annual aggregate potential cost of
requests denied was 82,771,608 New Israel Shekels (1 NIS = 4.6
USD). Requests for antineoplastic and immunomodulating
agents accounted for 36.37% of this sum. CONCLUSIONS: The
system was successfully implemented and facilitated standard-
ized approval criteria on the national level.
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OBJECTIVES: To empirically develop and validate the RxCost
Model, a prospective and concurrent risk assessment model that
uses claims-based diagnostic information to predict future phar-
macy expenditures for a US commercial population. Addition-
ally, we sought to empirically develop, validate, and compare the
Mixed RxCost (MRxCost) Model to explore the gain in predic-
tive power associated with adding drug information to the
RxCost Model. Prescription cost risk assessment models can be
used to proﬁle physician practices or control for comorbidity
burden in economic studies. METHODS: A retrospective longi-
tudinal cohort study using MEDSTAT MarketScan claims data
(1998–2000) for ambulatory persons who were continuously
enrolled for at least 13 months and were 18 to 64 years old was
used. A training sample consisting of over 1.3 million lives was
utilized to develop the models. Model coefﬁcients were devel-
oped from AHRQ clinical classiﬁcation software, clinical expert
panel, and stepwise OLS regression to screen noise variables. A
random holdout sample of 218,383 was utilized to validate the
models and to compare the performance of each model. Measure
of discrimination (R-squared), predictive ratios, and discrimina-
tion for hypothetical physician groups were computed and com-
pared to each other as well as to a Demographic-only model and
the proprietary DCG-HCC model. RESULTS: The R-square
value for the prospective RxCost, the MRxCost Model and the
DCG-HCC using the validation sample was 0.22, 0.34 and 0.16,
respectively and was 0.34 for the concurrent RxCost model. The
RxCost model’s predictive ratio’s varied between 0.93 and 1.05
for clinical subgroups and ranged from 1.03 to 1.04 across hypo-
thetical physician patient groups of size 10 to 500. CONCLU-
SIONS: The RxCost Model was successfully developed and it
outperformed the DCG-HCC model in terms of R-square after
re-calibrating the DCG-HCC model. The MRxCost Model also
proved that supplementing drug information can improve dis-
criminatory power.
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OBJECTIVES: To develop key performance indicators for the
Australian reimbursement system and to facilitate ongoing
analysis of the drug funding environment. METHODS: This
study involved the establishment of a relational database that
captured all relevant data over a 14-year period. This included
details of the Australian Pharmaceutical Beneﬁts Advisory Com-
mittee recommendations, listing criteria, product type, pricing,
type of economic evaluation, and public expenditure by product
type. A series of pricing indexes was also developed. The key
performance indicators are in the process of being developed
with input from industry and Government. These objectives are
consistent with the goals of the Free Trade Agreement between
Australia and the USA. RESULTS: The key performance indica-
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tors focus on providing the pharmaceutical industry with a
mechanism for assessing reward for innovation. They also assess
the pattern of new listings and changes in the structure of expen-
ditures under the Australian Pharmaceutical Beneﬁts Scheme.
The study shows that the average time from marketing approval
to reimbursement is 15 months, that expenditure by government
is driven mostly by volume increase for products that have been
listed for more than 12 months and not by recent listings or price
changes, and that products are more likely to be rejected if they
are assessed on a cost-effectiveness basis (42% approved) than
on a cost-minimisation basis (88% approved). CONCLUSIONS:
This is part of an ongoing effort to develop key performance
indicators and to date has been supported by industry and 
Government. In part, this is a response to the improved levels of
transparency and cooperation engendered by the Free Trade
Agreement between Australia and the USA.
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OBJECTIVES: To explore the relationship between the length of
a General Practitioner consultation and the number of prescrip-
tions issued. Initially it is necessary to establish if any trends exist
in prescriber activity and consultation length. METHODS: The
DIN-LINK database was used to obtain data on prescriber activ-
ity. DIN-LINK is a longitudinal patient database comprising over
3.8 million electronic patient records and is populated with data
from General Practices across Great Britain. This analysis was
based on patients consulting with a GP in the year to August
2004. Data on the number of prescriptions issued in a consulta-
tion in the database were stratiﬁed by consultation length, with
1–3 minutes being the lowest consultation length band, and
21–24 minutes the highest band. A 13–15 minute band was
included as it constituted the central value of this stratiﬁcation.
The unpaired student t-test was used to test for statistical sig-
niﬁcance between groups. RESULTS: The cohort for this analy-
sis comprised 467,446 patients, of whom 45% were male. The
mean age of the cohort was 42.4 years. Over the one-year period,
the cohort had 2,425,790 consultations, during which 2,181,974
prescriptions were issued. Statistically signiﬁcant differences in
the mean number of prescriptions per consultation were found
between the lowest and central band, and the lowest and highest
band (p < 0.001). At a consultation length of 1–3 minutes, 
GPs prescribed an average of 0.6 prescriptions per consultation.
This value peaked and plateaued at 1.1 prescriptions per con-
sultation at a consultation length of 13–15 minutes. CONCLU-
SIONS: Prescribing increased as consultation length increased up
to 13–15 minutes, after which a plateau in prescriber activity
was seen. This suggests that the incremental beneﬁt of consulta-
tions over 15 minutes may be limited. Further study is planned
with quantiﬁcation of the relationship between consultation
length and prescriber activity. Regression analysis is planned for
2005.
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OBJECTIVES: To assess trends in prescriber activity related to
patient smoking status and ACORN socio-economic status. The
ﬁndings will be used to identify variables for subsequent regres-
sion analysis of the relationship between prescriber activity and
consultation length. METHODS: The DIN-LINK database was
used to obtain detailed data on prescriber activity. DIN-LINK is
a longitudinal patient database comprising over 3.8 million elec-
tronic patient records, populated with data from General Prac-
tices across Great Britain. This analysis was based on patients
consulting with a GP in the year to August 2004. Patients were
stratiﬁed by smoking status and by ACORN socio-economic
classiﬁcation (CACI Ltd., www.caci.co.uk/acorn); measures of
prescriber activity were examined, including the number of pre-
scriptions per patient/per consultation, and the number of 
consultations per patient. The unpaired student t-test was used
to test for statistical signiﬁcant differences between groups.
RESULTS: The cohort comprised 467,446 patients, of which
339,275 had a record of smoking status and 415,418 had their
ACORN socio-economic status recorded. Among the sub-group
with smoking status recorded, signiﬁcant differences were found
between current smokers, non-smokers, and ex-smokers in mean
consultations per patient, prescriptions per patient, and pre-
scriptions per consultation. Although signiﬁcant results were
found, no trends were apparent. The only non-signiﬁcant com-
parisons were in mean prescriptions per consultation between
current smokers and ex-smokers, and in mean consultations 
per patient between current smokers and non-smokers. When
considering patients’ socio-economic status, those in the lowest
group (“Hard Pressed”) consulted more frequently and were
issued signiﬁcantly more prescriptions per head and signiﬁcantly
more prescriptions per consultation compared to the highest
ACORN group (“Wealthy Achievers”). CONCLUSIONS: We
found statistically signiﬁcant differences in prescriber activity
with respect to patients’ recorded smoking and socio-economic
status. Our ﬁndings have highlighted the potential of these two
factors as suitable variables for regression analysis planned for
2005.
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OBJECTIVE: The decision to prescribe one drug instead of
another within the same therapeutic class may be inﬂuenced by
a variety of drug-related, direct, or indirect factors; but little is
known about which considerations are most important in such
choices. The low-molecular-weight heparins (LMWHs) represent
a class of drugs that are commonly used and for which thera-
peutic equivalence has been debated in the literature. The
purpose of this study was to identify and compare factors per-
ceived by physicians and clinical pharmacists to be inﬂuential in
prescribing decisions among LMWHs. METHODS: Physicians
and clinical pharmacists were interviewed to elicit information
and rank factors that inﬂuence the prescribing and use of
LMWHs in community hospitals. For each factor, the mean and
median of the rating was determined along with the frequency
distribution across ratings. The nonparametric Mann-Whitney U
test was used to examine differences between physicians and clin-
ical pharmacists. RESULTS: Both groups considered efﬁcacy,
formulary status, and policies restricting drug use to be highly
inﬂuential in the decision to use one LMWH versus another.
Compared to clinical pharmacists, physicians rated personal
